Jane Street’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jane Street’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.08M	Buy	60,100 +48,200	+405%	+$745K	﹤0.01%	6380
2026 Q1	$165K	Buy	11,900 +1,800	+18%	+$25.3K	﹤0.01%	10305
2025 Q4	$122K	Buy	+10,100	New	+$137K	﹤0.01%	10070
2024 Q2	–	Sell	-78,100	Closed	-$222K	–	9277
2024 Q1	$222K	Sell	78,100 -1,865,000	-96%	-$24.4M	﹤0.01%	8040
2023 Q4	$28.6M	Buy	1,943,100 +962,500	+98%	+$14.8M	0.01%	998
2023 Q3	$18M	Buy	980,600 +6,400	+0.7%	+$135K	0.01%	1192
2023 Q2	$21M	Buy	974,200 +318,000	+48%	+$8.59M	0.01%	1163
2023 Q1	$19.3M	Buy	656,200 +33,900	+5%	+$1.18M	0.01%	1039
2022 Q4	$23M	Buy	622,300 +317,400	+104%	+$11.3M	0.01%	903
2022 Q3	$8.58M	Buy	304,900 +292,000	+2,264%	+$7.28M	﹤0.01%	1858
2022 Q2	$248K	Buy	+12,900	New	+$153K	﹤0.01%	7889

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jane Street's AMLX Position: Q2 2026 in Review

Jane Street opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 299,565 shares worth $5.38M. The stake represents ﹤0.01% of the portfolio and ranks #3609 among its holdings. This is a return to the name: Jane Street previously reported a position in AMLX as recently as Q4 2025.

Jane Street first reported a position in AMLX in Q1 2022 and has held it in 15 quarters since. The position peaked at $17M in Q4 2023. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Jane Street held 299,565 shares of Amylyx Pharmaceuticals worth $5.38M as of Q2 2026.
Amylyx Pharmaceuticals was a new Jane Street position in Q2 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #3609 holding.
Jane Street first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 15 quarters since.
Jane Street's Amylyx Pharmaceuticals position peaked at $17M in Q4 2023.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.